{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:55:35Z","timestamp":1790596535570,"version":"4.1.0"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Microsatellite-stable (MSS) colorectal cancer (CRC) accounts for approximately 85% of all CRC cases and exhibits limited responsiveness to immune checkpoint inhibitors (ICIs), representing a major challenge in current cancer immunotherapy. At the tumor-cell intrinsic level, low tumor mutational burden (TMB), impaired neoantigen generation, aberrant activation of oncogenic pathways such as WNT\/\u03b2-catenin signaling, and defects in interferon-\u03b3 signaling contribute to impaired immune recognition and immune escape. Within the TME, the accumulation of immunosuppressive populations, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), together with extracellular matrix remodeling and chemokine dysregulation, establishes an immune-excluded microenvironment that restricts effective antitumor immune responses. Furthermore, metabolic alterations, including enhanced glycolysis, lactate accumulation, and amino acid metabolic reprogramming, impair immune cell function and promote immunosuppression. Epigenetic modifications, including DNA methylation, histone remodeling, and non-coding RNA regulation, further contribute to the silencing of immune-related genes and reinforcement of immune evasion. In addition, recent advances in single-cell sequencing and spatial transcriptomics have provided unprecedented insights into the cellular heterogeneity and spatial organization of MSS CRC immune ecosystems. This review summarizes current knowledge regarding the molecular and cellular mechanisms driving immune resistance in MSS CRC and discusses future therapeutic opportunities for transforming immunologically \u201ccold\u201d MSS tumors into responsive immune microenvironments.<\/jats:p>","DOI":"10.3389\/fonc.2026.1893907","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:01:55Z","timestamp":1790593315000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanisms of immune resistance in microsatellite-stable colorectal cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Dongguang","family":"Niu","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Emergency Surgery, Qingdao Geriatric Hospital","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pediatric, Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zezhou","family":"Kuang","sequence":"additional","affiliation":[{"name":"Department of Emergency Surgery, Qingdao Geriatric Hospital","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huichang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Emergency Surgery, Qingdao Geriatric Hospital","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-024-01627-5","article-title":"Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial","volume":"17","author":"Bi","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215189","article-title":"Immunocheckpoint inhibitors in microsatellite-stable or proficient mismatch repair metastatic colorectal cancer: Are we entering a new era","volume":"15","author":"Matteucci","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100746","article-title":"High tumor mutation burden (TMB) in microsatellite stable (MSS) colorectal cancers: Diverse molecular associations point to variable pathophysiology","volume":"36","author":"Voutsadakis","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/edbk_349811","article-title":"Immunotherapy for microsatellite stable colorectal cancers: Challenges and novel therapeutic avenues","volume":"42","author":"Sahin","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1809947","article-title":"\u03b2-Catenin inhibition shapes tumor immunity and synergizes with immunotherapy in colorectal cancer","volume":"9","author":"Wang","year":"2020","journal-title":"Oncoimmunology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e36446","article-title":"Improving the efficacy of immunotherapy for colorectal cancer: Targeting tumor microenvironment-associated immunosuppressive cells","volume":"10","author":"Zou","year":"2024","journal-title":"Heliyon"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15225484","article-title":"Targeting myeloid-derived suppressor cell trafficking as a novel immunotherapeutic approach in microsatellite stable colorectal cancer","volume":"15","author":"Johnson","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1757513","article-title":"Myeloid-derived suppressor cells and regulatory T cells in colorectal cancer: a synergistic immunosuppressive axis and emerging therapeutic opportunities","volume":"17","author":"Zhang","year":"2026","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.b2300679","article-title":"Single-cell and spatial transcriptomic analysis reveals that an immune cell-related signature could predict clinical outcomes for microsatellite-stable colorectal cancer patients receiving immunotherapy","volume":"26","author":"Yuan","year":"2025","journal-title":"J Zhejiang Univ-Sci B"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27062689","article-title":"Single-cell multi-tissue T cell clonal dynamics reveal distinct immune coercion landscapes in MSI and MSS colorectal cancer","volume":"27","author":"Zhan","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02813-1","article-title":"Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7845","article-title":"Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial","volume":"9","author":"Fakih","year":"2023","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02261","article-title":"Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH)","volume":"42","author":"Xia","year":"2024","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejca.2022.12.004","article-title":"Phase 1b\/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases","volume":"181","author":"Guo","year":"2023","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7224","article-title":"PD-1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR\/MSS colorectal cancer","volume":"13","author":"Pei","year":"2024","journal-title":"Cancer Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1631620","article-title":"Research progress on immunotherapy combined with neoadjuvant concurrent chemoradiotherapy in pMMR\/MSS locally advanced rectal cancer","volume":"16","author":"He","year":"2025","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.6036075","article-title":"Phase II study of pembrolizumab plus capecitabine and bevacizumab for microsatellite stable\/mismatch repair-proficient metastatic colorectal cancer","volume":"25","author":"Bocobo","year":"2026","journal-title":"Clin Colorectal Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104108","article-title":"Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes","volume":"10","author":"Yamaguchi","year":"2025","journal-title":"ESMO Open"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00247-z","article-title":"Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer","volume":"2","author":"Westcott","year":"2021","journal-title":"Nat Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03386-7","article-title":"Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer","volume":"72","author":"Yu","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116958","article-title":"Inhibition of DNMTs increases neoantigen-reactive T-cell toxicity against microsatellite-stable colorectal cancer in combination with radiotherapy","volume":"177","author":"Huang","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7150\/thno.104722","article-title":"The allogenic non-proteinogenic amino acid BMAA-based vaccine breaks up the immune tolerance against colorectal cancer","volume":"15","author":"Tian","year":"2025","journal-title":"Theranostics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3393\/ac.2025.01354.0193","article-title":"Immunotherapy for microsatellite-stable colorectal cancer: overcoming resistance and exploring novel therapeutic strategies","volume":"42","author":"Kim","year":"2026","journal-title":"Ann Coloproctol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.009","article-title":"Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer","volume":"35","author":"Ambrosini","year":"2024","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008210","article-title":"Multiomic molecular characterization of the response to combination immunotherapy in MSS\/pMMR metastatic colorectal cancer","volume":"12","author":"Takei","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102534","article-title":"Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer","volume":"7","author":"Zhan","year":"2026","journal-title":"Cell Rep Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-026-01222-5","article-title":"CTMP-REV7 axis modulates MHC-I antigen presentation via CDK1-AKT crosstalk in MSI-L\/MSS colorectal cancer","volume":"49","author":"Gu","year":"2026","journal-title":"Cell Oncol (Dordr)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2023.102329","article-title":"Tumor immune evasion through loss of MHC class-I antigen presentation","volume":"83","author":"Sari","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202508040","article-title":"Personalized neoantigen vaccine plus regorafenib increases Rgs2+CD8+ T cells infiltration and reprograms the tumor microenvironment in microsatellite stable colorectal cancer liver metastases","volume":"12","author":"Chen","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13685","article-title":"Blockage of PD-L1 by FERMT3-mediated Wnt\/\u03b2-catenin signalling regulates chemoresistance and immune evasion of colorectal cancer cells","volume":"49","author":"Tang","year":"2022","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"10259","DOI":"10.1038\/s41467-024-54710-3","article-title":"Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients","volume":"15","author":"Feng","year":"2024","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-22-0644","article-title":"\u03b2-Catenin drives butyrophilin-like molecule loss and \u03b3\u03b4 T-cell exclusion in colon cancer","volume":"11","author":"Suzuki","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1186\/s12885-020-07537-2","article-title":"The majority of \u03b2-catenin mutations in colorectal cancer is homozygous","volume":"20","author":"Arnold","year":"2020","journal-title":"BMC Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194906","article-title":"Combination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal cancer","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-026-01419-6","article-title":"USP21 drives immune evasion in colorectal cancer via deubiquitination and stabilization of \u03b2-catenin","volume":"23","author":"Zhou","year":"2026","journal-title":"Cell Mol Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02502-8","article-title":"Immune-related deubiquitylation spectrum of microsatellite stability colorectal cancer reveals USP7 as a potential immunotherapeutic target","volume":"25","author":"Yin","year":"2025","journal-title":"Mol Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02806-3","article-title":"ASCL2 induces an immune excluded microenvironment by activating cancer-associated fibroblasts in microsatellite stable colorectal cancer","volume":"42","author":"Zhang","year":"2023","journal-title":"Oncogene"},{"key":"B40","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12967-023-04606-5","article-title":"BRAF D594A mutation defines a unique biological and immuno-modulatory subgroup associated with functional CD8(+) T cell infiltration in colorectal cancer","volume":"21","author":"Li","year":"2023","journal-title":"J Transl Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41421-023-00605-4","article-title":"Single cell dynamics of tumor specificity vs bystander activity in CD8(+) T cells define the diverse immune landscapes in colorectal cancer","volume":"9","author":"Borr\u00e0s","year":"2023","journal-title":"Cell Discov"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001895","article-title":"Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13527-y","article-title":"IL-6 levels correlate with prognosis and immunosuppressive stromal cells in patients with colorectal cancer","volume":"30","author":"Yamamoto","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02380-2","article-title":"TGF-\u03b2 builds a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1(+) macrophages","volume":"57","author":"Henriques","year":"2025","journal-title":"Nat Genet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03081-5","article-title":"TGF-\u03b2 orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer","volume":"71","author":"Gneo","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12130","article-title":"S100A8 promotes epithelial-mesenchymal transition and metastasis under TGF-\u03b2\/USF2 axis in colorectal cancer","volume":"41","author":"Li","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-026-02671-y","article-title":"LISS enables immune evasion of colorectal cancers irrespective of MSI status","volume":"11","author":"Lin","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3892\/ol.2022.13628","article-title":"Interference with pathways activated by topoisomerase inhibition alters the surface expression of PD-L1 and MHC I in colon cancer cells","volume":"25","author":"Hassan","year":"2023","journal-title":"Oncol Lett"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.7554\/elife.79811","article-title":"VPS9D1-AS1 overexpression amplifies intratumoral TGF-\u03b2 signaling and promotes tumor cell escape from CD8(+) T cell killing in colorectal cancer","volume":"11","author":"Yang","year":"2022","journal-title":"Elife"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112754","article-title":"Dominant negative TGF-\u03b2 receptor type II in T lymphocytes promotes anti-tumor immunity by modulating T cell subsets and enhancing CTL responses","volume":"148","author":"Li","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13062-023-00401-w","article-title":"ILC1-derived IFN-\u03b3 regulates macrophage activation in colon cancer","volume":"18","author":"Zhang","year":"2023","journal-title":"Biol Direct"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1175513","article-title":"Cytokine concentration in peripheral blood of patients with colorectal cancer","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s12672-025-02452-z","article-title":"Increased protein expression of interleukin-10 and its signalling molecules in colon cancer progression: potential prognostic and therapeutic targets","volume":"16","author":"Aslam","year":"2025","journal-title":"Discov Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.11.024","article-title":"Interleukin-10 deficiency suppresses colorectal cancer metastasis by enriching gut Parabacteroides distasonis","volume":"76","author":"Yu","year":"2025","journal-title":"J Adv Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.02.052","article-title":"IL-4\/Stat6 activities correlate with apoptosis and metastasis in colon cancer cells","volume":"369","author":"Li","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4429","article-title":"E2F1\/SP3\/STAT6 axis is required for IL-4-induced epithelial-mesenchymal transition of colorectal cancer cells","volume":"53","author":"Chen","year":"2018","journal-title":"Int J Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-026-08795-x","article-title":"Multi-omics reveals CXCR4 drives immune escape in colorectal cancer via metabolic reprogramming and immune microenvironment remodeling","volume":"17","author":"Zhu","year":"2026","journal-title":"Cell Death Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-026-00375-5","article-title":"STAMBP drives colorectal cancer progression via CXCR4 deubiquitination and bone marrow-derived suppressor cell recruitment","volume":"27","author":"Yang","year":"2026","journal-title":"Genes Immun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.147692","article-title":"Colorectal cancer tumor cell-derived exosomal miR-203a-3p promotes CRC metastasis by targeting PTEN-induced macrophage polarization","volume":"885","author":"Pei","year":"2023","journal-title":"Gene"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1186\/s12967-025-07309-1","article-title":"CXCL12 deficiency promotes colorectal cancer progression and reduces anti-PD-L1 immunotherapy efficacy through MDSC regulation","volume":"23","author":"Zhao","year":"2025","journal-title":"J Transl Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.111827","article-title":"Tumor-derived colorectal cancer organoids induce a unique Treg cell population by directing CD4(+) T cell differentiation","volume":"28","author":"Revilla","year":"2025","journal-title":"iScience"},{"key":"B62","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s13046-019-1372-z","article-title":"Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer","volume":"38","author":"Zaravinos","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17105","article-title":"Tumor infiltrating effector regulatory T cells express VEGF receptor 2 in patients with colorectal cancer","volume":"44","author":"Tsumuraya","year":"2024","journal-title":"Anticancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03182-9","article-title":"Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer","volume":"71","author":"Thibaudin","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112639","article-title":"IL-2 immunotherapy rescues irradiation-induced T cell exhaustion in mouse colon cancer","volume":"28","author":"Yong","year":"2025","journal-title":"iScience"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109272","article-title":"LC3-dependent extracellular vesicles promote M-MDSC accumulation and immunosuppression in colorectal cancer","volume":"27","author":"Gu","year":"2024","journal-title":"iScience"},{"key":"B67","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12029-025-01207-x","article-title":"The dynamic changes of circulating myeloid-derived suppressor cells (MDSCs) subsets in colorectal cancer patients undergoing oxaliplatin-based chemotherapy","volume":"56","author":"Gunarsa","year":"2025","journal-title":"J Gastrointest Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.advms.2021.12.005","article-title":"The effect of l-arginine supplementation and surgical trauma on the frequency of myeloid-derived suppressor cells and T lymphocytes in tumour and blood of colorectal cancer patients","volume":"67","author":"Szefel","year":"2022","journal-title":"Adv Med Sci"},{"key":"B69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.trsl.2026.02.006","article-title":"Targeting MAFB potentiates immune checkpoint inhibitor efficacy by reprogramming tumor-associated macrophages to an M1-like phenotype in colorectal cancer","volume":"289","author":"Choi","year":"2026","journal-title":"Transl Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1779388","article-title":"Targeting the chemokine-Treg axes in tumor immune evasion: from mechanisms to therapeutic opportunities","volume":"17","author":"Lian","year":"2026","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2723264","article-title":"IL1RN and PRRX1 as a prognostic biomarker correlated with immune infiltrates in colorectal cancer: evidence from bioinformatic analysis","volume":"2022","author":"Wang","year":"2022","journal-title":"Int J Genomics"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-337038","article-title":"SPP1(+) macrophages facilitate the differentiation and maturation of regulatory T cells in tumour-draining lymph nodes of colorectal cancer","author":"Wang","year":"2026","journal-title":"Gut"},{"key":"B73","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.canlet.2021.07.006","article-title":"Stromal fibroblasts shape the myeloid phenotype in normal colon and colorectal cancer and induce CD163 and CCL2 expression in macrophages","volume":"520","author":"Stadler","year":"2021","journal-title":"Cancer Lett"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137001","article-title":"Pexidartinib and immune checkpoint inhibitors combine to activate tumor immunity in a murine colorectal cancer model by depleting M2 macrophages differentiated by cancer-associated fibroblasts","volume":"25","author":"Shimizu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-329147","article-title":"Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity","volume":"72","author":"Li","year":"2023","journal-title":"Gut"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15204943","article-title":"TIM-3 expression and M2 polarization of macrophages in the TGF\u03b2-activated tumor microenvironment in colorectal cancer","volume":"15","author":"Katagata","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116883","article-title":"Rapamycin circumvents anti PD-1 therapy resistance in colorectal cancer by reducing PD-L1 expression and optimizing the tumor microenvironment","volume":"176","author":"Jia","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B78","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1158\/0008-5472.can-24-4916","article-title":"SPP1 drives colorectal cancer liver metastasis and immunotherapy resistance by stimulating CXCL12 production in cancer-associated fibroblasts","volume":"86","author":"Liu","year":"2026","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","article-title":"Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer","volume":"13","author":"Qi","year":"2022","journal-title":"Nat Commun"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216985","article-title":"Colorectal cancer-associated fibroblasts inhibit effector T cells via NECTIN2 signaling","volume":"595","author":"Agorku","year":"2024","journal-title":"Cancer Lett"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2022.1610350","article-title":"Cancer-associated stromal fibroblast-derived transcriptomes predict poor clinical outcomes and immunosuppression in colon cancer","volume":"28","author":"Wang","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1186\/s12967-025-06863-y","article-title":"Cancer cell SPOCD1 promotes colorectal cancer liver metastasis by activating the CXCL12\/CXCR4 signaling pathway in cancer-associated fibroblasts","volume":"23","author":"Peng","year":"2025","journal-title":"J Transl Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/biof.70012","article-title":"Spatial and single-cell transcriptomic analysis reveals fibroblasts dependent immune environment in colorectal cancer","volume":"51","author":"Jia","year":"2025","journal-title":"Biofactors"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013763","article-title":"Single-cell and spatial transcriptome profiling identifies the immunosuppressive spatial niche in KRAS-mutant colorectal cancer","volume":"13","author":"Yang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00262-024-03925-w","article-title":"IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization","volume":"74","author":"Guangzhao","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030498","article-title":"Metabolic singularities in microsatellite-stable colorectal cancer: identifying key players in immunosuppression to improve the immunotherapy response","volume":"17","author":"Gorr\u00eda","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33831","article-title":"Aberrant DNA methylation patterns in microsatellite stable human colorectal cancers define a new marker panel for the CpG island methylator phenotype","volume":"150","author":"Gebhard","year":"2022","journal-title":"Int J Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1039631","article-title":"Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.ccell.2025.02.023","article-title":"Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"B90","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41698-024-00743-2","article-title":"DDR1 is identified as an immunotherapy target for microsatellite stable colon cancer by CRISPR screening","volume":"8","author":"Wu","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-025-00964-y","article-title":"Bacillus Calmette-Guerin induces CD8+ T cell infiltration and suppresses tumor progression in microsatellite stable colorectal cancer by downregulating ARID1A","volume":"32","author":"Xie","year":"2025","journal-title":"Cancer Gene Ther"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-2404","article-title":"ARID1A mutation may define an immunologically active subgroup in patients with microsatellite stable colorectal cancer","volume":"27","author":"Mehrvarz Sarshekeh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3233\/cbm-210408","article-title":"Comprehensive analysis of negatively correlated miRNA-mRNA regulatory pairs associated with microsatellite instability in colorectal cancer","volume":"34","author":"Liu","year":"2022","journal-title":"Cancer biomark"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2026-338195","article-title":"PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer","author":"Cai","year":"2026","journal-title":"Gut"},{"key":"B95","volume-title":"Preliminary safety and efficacy of upfront FOLFOXIRI and bevacizumab with cadonilimab in patients with proficient mismatch repair\/microsatellite stable (pMMR\/MSS) metastatic colorectal cancer: A multicenter phase II study (SYLT-026)","author":"Lin","year":"2025"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.medj.2024.05.009","article-title":"First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2\/3 trial","volume":"5","author":"Wang","year":"2024","journal-title":"Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/jco.2024.42.3_suppl.124","article-title":"First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2\/3 study","volume":"42","author":"Xu","year":"2024"},{"key":"B98","volume-title":"Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer","author":"Yuki","year":"2020"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00377-3","article-title":"Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer","volume":"6","author":"Chen","year":"2021","journal-title":"Signal Transduction Targeted Ther"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010826","article-title":"Disruption of GPSM1\/CSF1 signaling reprograms tumor-associated macrophages to overcome anti-PD-1 resistance in colorectal cancer","volume":"13","author":"Chen","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13121231","article-title":"Personalized cancer vaccines: Current advances and emerging horizons","volume":"13","author":"Lu","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3940","article-title":"Phase I trial of viral vector-based personalized vaccination elicits robust neoantigen-specific antitumor T-cell responses","volume":"30","author":"D'Alise","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: The evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"key":"B105","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: Current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32020088","article-title":"The role of the DNA methyltransferase family and the therapeutic potential of DNMT inhibitors in tumor treatment","volume":"32","author":"Kim","year":"2025","journal-title":"Curr Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1072651","article-title":"Recent progress in DNA methyltransferase inhibitors as anticancer agents","volume":"13","author":"Zhang","year":"2022"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.06.023","article-title":"Preferential response of cancer cells to zebularine","volume":"6","author":"Cheng","year":"2004","journal-title":"Cancer Cell"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav2588","article-title":"Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion","volume":"366","author":"Leone","year":"2019","journal-title":"Science"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.62347\/zsoo2247","article-title":"Role of amino acid metabolism in tumor immune microenvironment of colorectal cancer","volume":"15","author":"Zhu","year":"2025","journal-title":"Am J Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1640073","article-title":"Indoleamine 2,3-dioxygenase 1 in cancer immunotherapy: From small-molecule inhibition to PROTAC-mediated degradation","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharmacol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800630","article-title":"Indoleamine 2,3-dioxygenase 1: A promising therapeutic target in Malignant tumor","volume":"12","author":"Song","year":"2021","journal-title":"Front Immunol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41522-025-00786-8","article-title":"Gut microbiota shapes cancer immunotherapy responses","volume":"11","author":"Lei","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B115","volume-title":"Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study","author":"Segal","year":"2025"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1893907\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:01:57Z","timestamp":1790593317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1893907\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":115,"alternative-id":["10.3389\/fonc.2026.1893907"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1893907","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1893907"}}